Comments
Drug firm Unichem Laboratories has lined up a capex of around ₹350 crore for the next two years as it plans to strengthen R&D activity and expand operations in the US market.
The company, which focuses on various therapeutic segments like gastroenterology and cardiology, expects its US revenues to cross $100 million over the next few years. The long term aim of the company is to cross $500 million in revenues from the US operations.
“One major capex is the API expansion, which is going on, the new plant which is coming up as well as on the formulation side and existing API site,” Unichem Laboratories Chief Finance and Compliance Officer Rakesh Parikh said in a analyst call.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.